NewAmsterdam Pharma Company N.V.
NASDAQ:NAMSBiotechnology
+$0.12 today
- Market cap
- $2.37B
- Beta
- 0.08
- P/E (TTM)
- -17.2
- EPS (TTM)
- -$1.76
Volume 1.80M
Average 1.21M
NAMS Operating Cash Flow
Cash generated by the company's core business operations during the period.
NewAmsterdam Pharma Company N.V.NASDAQ: NAMS
Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Operating cash flow grows, but more slowly than its trailing trend
Q2 FY2026 operating cash flow of $39.21M (cash outflow) rose 4.1% year over year, behind the +15.6% change in trailing-twelve-month operating cash flow. Sequentially, it rose 28.1% from the prior quarter.
Context
- Operating cash flow amounted to 656.7% of revenue in FY2025, up 308.7 pp from a year earlier.
- Operating cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +4.1% toward the trailing-twelve-month pace of +15.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (147.78M) USD
- Year-over-year change
- +6.8%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (147.78M) | +6.8% |
| FY2024 | 2024-12-31 | (158.56M) | -12.3% |
| FY2023 | 2023-12-31 | (141.22M) | -1424.1% |
| FY2022 | 2022-12-31 | 10.67M | +136.1% |
| FY2021 | 2021-12-31 | (29.51M) | — |
Operating Cash Flow vs competitors
How NAMS compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.6% is the 4th highest of 9, against a peer median of -3.1%.
- Operating cash flow amounts to 2014.6% of revenue for NAMS, versus a peer median of 210.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $434.04M USD | +24.1% | +19.0% | 12043.3% | |
| LTM Jun 2026 | $418.44M USD | +174.3% | +79.2% | — | |
| LTM Jun 2026 | $197.72M USD | -35.7% | -5.5% | 15.4% | |
| LTM Jun 2026 | $143.46M USD | +15.6% | — | 2014.6% | |
| LTM Sep 2026 | $129.88M USD | -15.9% | -11.8% | — | |
| LTM Mar 2026 | $105.55M USD | +3.0% | +48.7% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $88.31M USD | +66.0% | +31.2% | 856.0% |
SEPNSepterna, Inc. | LTM Sep 2026 | $76.57M USD | -173.5% | — | 79.5% |
| FY2025 | A$11.45M AUD | -9.2% | -2.5% | 210.5% | |
| Peer median (excluding NAMS) | — | -3.1% | +19.0% | 210.5% | |
Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (41.79M) | (22.63M) | (176.94M) | (241.6M) | (203.82M) |
| Depreciation & Amortization | 5K | 9K | 49K | 113K | 220K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.24M | 4.12M | 24.57M | 33.62M | 59.43M |
| Change in Working Capital | 4.47M | 10.37M | 5.87M | (32.67M) | (7.94M) |
| Accounts Receivables | 0 | (4.18M) | 4.03M | 0 | (13.28M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 6.56M | 4.81M | 5.07M | (12.95M) | 4.91M |
| Other Working Capital | (2.09M) | 9.75M | (3.23M) | (19.73M) | 427K |
| Other Non-Cash Items | 6.55M | 18.8M | 5.23M | 81.98M | 4.34M |
| Operating Cash Flow | (29.51M) | 10.67M | (141.22M) | (158.56M) | (147.78M) |
| Capital Expenditures | (24K) | (221K) | (24K) | (672K) | (246K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (62.18M) | (296.73M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 122.06M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (24K) | (221K) | (24K) | (62.85M) | (174.92M) |
| Debt Repayment | 0 | 747K | 0 | 0 | 0 |
| Common Stock Issued | 84.7M | 396.95M | 8.91M | 645.51M | 29.52M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (5.79M) | 0 | 14M | 0 |
| Financing Cash Flow | 84.7M | 391.91M | 8.91M | 659.51M | 29.52M |
| Effect of Forex Changes | (4.68M) | 5.25M | 5.05M | (6.8M) | 12.76M |
| Net Change in Cash | 50.49M | 407.6M | (127.28M) | 431.29M | (280.42M) |
| Free Cash Flow | (29.54M) | 10.44M | (141.24M) | (159.24M) | (148.03M) |
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
Intrinsic Alpha fair value
Locked
Current Price
$19.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.